Evercore ISI Analyst Breaks Down Amgen's IPR Against AbbVie's Humira Formulation Patent
June 29, 2015 at 14:44 PM EDT
Last Friday, Amgen, Inc. (NASDAQ: AMGN) filed an intellectual property rights (IPR) suit against AbbVie Inc (NYSE: ABBV)’s ...